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Fusion genes result from genomic rearrangements, such as translocations or inversions. On the 
transcript level, fusions arise from accidental read-through and trans-splicing events. In acute myeloid 
leukemia (AML), fusion genes are found in around 30% of patients constituting major biomarkers for 
diagnosis, prognosis and treatment decisions. Furthermore, studies have shown the relevance of gene 
expression profiles for the distinction of AML subtypes and risk assessment of the patients. This 
dissertation is focused on fusion gene detection and gene expression analysis by transcriptome 
sequencing (RNA-seq) of large AML patient cohorts.  
In the first chapter, we analyzed the expression of SMARCA5 in AML patients and performed knockout 
experiments using leukemic cell lines. We found a positive correlation between the expression levels 
of proliferation biomarkers and SMARCA5. In addition, we observed shorter overall survival of patients 
with high SMARCA5 expression. Knockout experiments showed decreased proliferation and growth of 
leukemic cells lacking SMARCA5. Therefore, we concluded that SMARCA5 might have prognostic 
relevance and constitutes a potential target for inhibition treatment of AML patients with high 
SMARCA5 expression.  
In chapter 2, we analyzed the performance of fusion gene detection by RNA-seq in nearly a thousand 
AML patient samples. Therefore, data from clinical routine diagnostics was compared to results from 
fusion callers (i.e., Arriba, FusionCatcher) showing high sensitivity (90%) of fusion gene detection by 
RNA-seq. Moreover, RNA-seq identified AML-related fusion genes in 26 cases that were not reported 
by routine diagnostics. However, fusion calling from sequencing data usually yields many false positive 
events. Therefore, we established a detection pipeline with fine-tuned filtering strategies enabling the 
identification of 157 robust fusion candidates and the discovery of NRIP1-MIR99AHG, a novel recurrent 
fusion gene in AML. 
Chapter 3 presents the filtering strategies and the workflow for the detection of robust fusion gene 
candidates by RNA-seq. The filtering metrics Promiscuity Score (PS), Fusion Transcript Score (FTS) and 
Robustness Score (RS), which were developed in this study, use properties such as expression and 
frequencies of fusion events to assign evidence levels to the detected fusion genes. This enabled 
substantial reduction of putative false positive fusion calls and allowed for robust identification of 
novel fusions as demonstrated in chapter 2. Furthermore, all required tools and modules of the 
workflow were bundled into a publicly available software package for simple execution in different 
system environments. 
This thesis highlights the power of RNA-seq for gene expression analyses and fusion gene detection in 






Due to higher precision, lower costs and shorter runtime, next-generation sequencing (NGS) is 
becoming increasingly popular. NGS enables sensitive and comprehensive genetic analyses providing 
a valuable tool for clinical diagnostics of genetic disorders. Millions of reads generated by NGS contain
detailed structural information of the genome (DNA-seq) or transcriptome (RNA-seq) with a resolution 
of single base pairs. NGS enables the identification and quantification of transcribed genes, as well as 
more specific analyses such as the detection of single-nucleotide variants (SNV), structural variants 
(SV), fusion genes, differential/alternative splicing, allelic imbalances, etc. Furthermore, targeted NGS 
assays allow for further cost reduction and shorter runtime while sensitivity and precision can be 
increased due to on-target focused sequencing power. Several studies explored the applicability of 
these targeted assays in clinical settings, demonstrating the added value in diagnostics of 
hematological malignancies1–5. Nevertheless, novel genetic lesions are not captured by targeted 
approaches and unusual aberrations, not covered by these assays, might be missed. In general, the 
workflow of processing NGS data (Figure 1) can be divided into the following steps: (I) Removal of low-
quality reads and trimming of low-quality bases. (II) Mapping of the reads to a reference sequence. (III)
Primary analyses such as quantification of sequence coverage and identification of differences 
between the mapped reads and the reference. (IV) Secondary analyses. 
Figure 1: General pipeline for processing next-generation sequencing data divided into the steps: (I) Quality filtering and read 
trimming, (II) Mapping, (III) Primary Analyses, (IV) Secondary Analyses.
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The vast repertoire of computational methods to process NGS data complicates the establishment of 
standardized analyses. In addition to the variety of sequence mapping and downstream analyses 
methods, many parameters within the tools can be fine-tuned to improve sensitivity and/or reduce 
false positives. Several studies have been conducted to comprehensively compare and evaluate 
different algorithms in various settings but overall, no standard approach has been established so far. 
It was rather concluded that performance is dependent on underlying properties of the sequencing 
data (e.g., organism, read length, sequencing technology) and the selection of proper settings based 
on study design6–9. Moreover, efforts have been made to develop applications merging several 
analyses into one pipeline providing a simplified tool for an extensive diagnostic workup of patients' 
genomic data10,11. 
In the last decade, NGS has tremendously advanced our knowledge about hematopoietic and other 
genetic diseases, enabling ever more accurate assessment of individual genetic aberrations and the 
development of tailored treatments. What is more, third-generation sequencing methods are on the 
rise e.g., Oxford Nanopore. This technology generates long reads with lengths of tens of kilobases in 
contrast to NGS producing reads of usually 100 to 200 bases in length. Longer reads allow for more 
accurate and complete assembly of the genome and genomic transcripts. By all means, the significance 
of NGS as an additional diagnostic method of hematological malignancies in clinical applications has 
already been demonstrated12–15. Therefore, progressive improvements and increasing application of 
NGS in clinical routine will inevitably become a new standard in precision oncology. 
Acute myeloid leukemia 
AML is a hematological disease characterized by impaired maturation and clonal expansion of myeloid 
progenitor cells (i.e., myeloblasts). The inability of these cells to differentiate into mature blood cells 
such as erythrocytes, megakaryocytes, macrophages or granulocytes, and their increased proliferation 
suppresses the production of normal blood cells. AML is a heterogeneous disease and subgroups were 
initially defined by the French-American-British (FAB) co-operative group16 but mostly replaced by a 
classification of the World Health Organization (WHO) which included genetic aberrations17,18. In 
addition, the European LeukemiaNet (ELN) has published recommendations on the management and 
risk stratification of AML19,20. 
Cytogenetically normal (CN) patients (40-50% of AML cases) are characterized by small genetic changes 
e.g., single base mutations. Previous studies comprehensively explored the mutational landscape of 
AML and identified hundreds of recurrent disease-defining lesions21–23 showing that the broad 
spectrum and variable co-occurrence of these small somatic aberrations substantially contribute to 
the heterogeneity of AML. Commonly mutated genes are NPM1, FLT3 and DNMT3A. Mutated NPM1 
was defined as a distinct class by the WHO and is associated with favorable risk (without the co-
occurrence of FLT3 internal tandem duplications or other adverse risk factors). This gene primarily 
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resides in the nucleolus and is involved in multiple cellular processes such as ribosome biogenesis, 
preservation of genomic stability, p53-dependent stress response and modulation of growth-
suppressive pathways24. Although the precise leukemogenic mechanism of mutated NPM1 has not yet 
been identified, aberrations of NPM1 were found to impair its function in maintaining genome 
stability25 and induce delocalization of the protein to the cytoplasm26. Furthermore, mutated NPM1 
requires cooperating aberrations in leukemogenesis24 and is mostly found in co-occurrence with 
mutations in FLT3 and/or DNMT3A27. Small mutations are rarely mutually exclusive and often occur 
together with other larger aberrations such as translocations, inversions or deletions, which is crucial 
for risk stratification and treatment strategy. 
AML patients are usually treated with chemotherapy to reduce the leukemic burden and achieve 
complete remission (CR) which is commonly defined by the abundance of 5% blasts in the bone 
marrow. The rate of patients achieving CR is around 64%, and younger patients or favorable risk group 
patients show higher treatment response rates (73%)28. Nevertheless, depending on age and risk 
group, relapse rates range from 30% to 80%29 and the majority of patients decease within 5 years after 
diagnosis30. Initial treatment strategies have not substantially changed over the past decades, 
consisting of an induction therapy with anthracycline and cytarabine for young adults and medically fit 
elderly patients. After achieving CR, consolidation treatment of several cycles with high-dose 
cytarabine and/or stem cell transplantation (SCT) aims to prevent or to delay relapse, which eventually 
occurs in the majority of patients. However, alternative treatment strategies of AML subtypes have 
been shown to improve response and survival of patients. For example, patients with acute 
promyelocytic leukemia (APL), characterized by a PML-RARA fusion, are commonly treated with all-
trans retinoic acid (ATRA) and achieve CR in 80-100% of cases31,32. ATRA induces degradation of the 
PML-RARA oncoprotein and restores transcription of genes that are involved in myeloid 
differentiation, thereby reconstituting normal blood production. The introduction of ATRA for the 
treatment of APL was a pioneering step towards personalized medicine and emphasizes the need for 
precise tumor diagnostics as well as targeted treatment approaches. Furthermore, inhibition of specific 
mutant proteins resulting from alterations in FLT3, IDH or nuclear exporters shows promising results 
with regards to outcome of the corresponding AML subgroups33–36. Besides SCT, the most established 
immunotherapy for AML, targeted immunotherapies are on the rise showing exciting results in other 
entities such as chronic lymphoblastic leukemia37 and are currently under investigation for the use in 
AML38,39. The aim is to immunologically eradicate malignant cells in a targeted manner by e.g., chimeric 
antigen receptor T-cells that are designed to bind tumor-specific antigens. 
Taken together, AML is a highly heterogenous disease requiring tailored treatment strategies that are 
based on risk stratification deduced from clinical parameters and more importantly, thorough 
identification of the mutational profile and other genetic abnormalities of the individual patients. 
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Fusion genes in AML 
Fusion genes emerge from rearrangements of chromosomal regions (e.g., translocation, inversion) 
whereby the breakpoints are located within or in proximity of affected genes. However, fusion genes 
may also arise from intergenic splicing events without any disruption of the genome40. The first fusion 
genes were discovered by the identification of the recurrent translocation t(9;22)(q34;q11) in chronic 
myeloid leukemia (CML) resulting in a BCR-ABL1 fusion and the recurrent translocation 
t(8;21)(q22;q22.1) in AML resulting in a RUNX1-RUNX1T1 fusion41–44. These milestones led to further 
discoveries of disease-defining fusion genes, not only in hematological entities but also in solid 
tumors45,46, and laid the foundation for targeted treatments. For example, the BCR-ABL1 protein can 
be targeted by Imatinib which inhibits ATP-binding of the fusion protein, thereby preventing its 
oncogenic effect and inducing apoptosis of the affected cells. In AML, fusion genes occur in a third of 
all cases (Figure 2) constituting important diagnostic and prognostic biomarkers. 
 
 
Figure 2: Distribution of biological and prognostic subgroups in a cohort study of 5876 AML patients27. Other 
subsets include subgroup-defining alterations that are not resulting in transcribed fusion genes. 
 
The most recurring fusions are RUNX1-RUNX1T1, CBFB-MYH11, PML-RARA, DEK-NUP214 and fusions 
involving KMT2A. DEK-NUP214 and KMT2A fusions result from translocations t(6;9)(p23;q34.1) and 
t(-;11)(-;q23.3), respectively. While these fusions constitute adverse risk and affected individuals have 
a poor prognosis, RUNX1-RUNX1T1 and CBFB-MYH11, resulting from t(8;21)(q22;q22.1) and 
inv(16)(p13.1q22)/t(16;16)(p13.1;q22), are fusion genes associated with favorable outcome. 
Moreover, t(15;17)(q24;q21) forming a PML-RARA fusion and found in 95% of APL cases, is regarded 
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remarkable CR and cure rates32,47. However, resistance to ATRA and ATO has been observed. In some 
instances, this could be driven by pre-existing or acquired mutations in PML or RARA48–50 but also other 
driver genes51,52. Furthermore, other RARA fusions in APL, such as GTF2I-RARA and PLZF-RARA, have 
also shown insensitivity to ATRA53–55. This emphasizes the critical relevance of accurate and complete 
capturing of genetic aberrations in clinical diagnostics for proper assessment of treatment options. So 
far, there are no therapies targeting other AML-related fusions. 
Current standard in AML diagnostics 
Clinical routine diagnostics of AML patients includes initial microscopic inspection of cells from bone 
marrow or peripheral blood smears and the identification of potential leukemic cells based on 
cytomorphology. Further, cellularity, histotopography and distribution of immature and mature 
hematopoietic stem cells are used to identify different hematological disorders. In example, AML is 
determined by a myeloblast count 17, as defined by the WHO. However, recurrent 
rearrangements t(15;17), t(8;21) and inv(16)/t(16;16), resulting in PML-RARA, RUNX1-RUNX1T1 and 
CBFB-MYH11 fusions, respectively, are sufficient to diagnose AML, regardless of the blast count. Blast 
lineages and maturation state can be inferred from immunophenotyping which is the measurement of 
specific surface antigens. To this end, cells are labeled with fluorophore-conjugated antibodies 
targeting surface markers of interest and are subsequently quantified by flow cytometry. This allows 
for discrimination of cell populations and the identification of specific immunophenotypes, guiding 
more specialized aberration screenings such as FISH and PCR. Therefore, immunophenotyping by flow 
cytometry is a crucial initial step in diagnosis of hematological diseases and is also used for minimal 
residual disease monitoring. 
Chromosomal G-banding (Karyotyping) is a technique based on microscopic analysis of metaphase 
chromosomes allowing for detection of larger SV such as deletions, duplications, translocations, 
inversions or aneuploidy. Of note, Karyotyping requires culture of leukemia cells which is not always 
successful. FISH is used to identify known or suspected rearrangements and numerical aberrations by 
fluorescently labeled probes. FISH can be applied to metaphase spreads from cultured cells as well as 
to interphase nuclei from cells directly spread on a slide with the latter allowing for higher cell counts. 
While FISH is a targeted approach, Karyotyping provides genome-wide analyses but is less sensitive 
since the resolution is approximately 5-10 Mb56 and the analysis is typically limited to 25 metaphases. 
A further crucial diagnostic technique in clinical routine is PCR which is a targeted approach and offers 
very high sensitivity. Thereby, particular sequences of DNA or cDNA (reverse transcribed RNA) are 
targeted by specific primers and amplified enabling the identification of SNV, SV or the detection of 
specific transcripts (e.g., fusions) which can be quantified (qPCR, microarrays) and monitored. 
Complementary utilization of these techniques in contemporary clinical routine is essential for AML 
diagnostics and lays the foundation for risk stratification and treatment strategies. 
8 Introduction
Fusion gene detection by RNA-seq 
Fusion gene detection by RNA-seq allows for systematic examination of the entire transcriptome, is 
not limited to specific targets and has the potential for discovery of novel fusion transcripts. However, 
fusion detection by RNA-seq is computationally challenging and is based on the detection of chimeric 
sequences. Therefore, fusion calling algorithms need to identify reads whose subsequences map to 
different locations in the transcriptome, defined as fusion spanning reads or fusion spanning pairs 
(Figure 3).
Figure 3: Illustration of paired-end RNA-seq reads mapped to two gene loci. Fusion supporting reads are highlighted 
in orange. A Fusion spanning pair is characterized by one read mapping to a gene locus other than its partner read. 
A read whose subsequences map to different gene loci is defined as a fusion spanning read. 
Several technical factors might influence the accuracy of this procedure such as sequencing errors and
artifacts derived from erroneous sequence amplification, potentially resulting in false mappings. 
Furthermore, biological factors such as polymorphic genes, homologous regions and highly expressed 
genes might contribute to false positive fusion calls7. Over the last decade, many tools have been 
developed for the identification of fusion genes in RNA-seq data. Comparative evaluation of these tools
on real and synthetic sequencing data demonstrated overall good performance with a sensitivity of 
around 90%57–59. However, only a low proportion of fusion events were called consistently by the
different tools and therefore, the authors recommended to utilize several callers for robust fusion 
detection analyses. The low overlap of identified fusion events between the tools suggests a high rate 
of false positive calls which requires proper filtering strategies. Current filtering approaches offered by 
the tools are based on read coverage, built-in scoring dependent on individual parameters, proportion 
of spanning reads and spanning pairs, annotation of partner genes involved in the fusion or blacklists 
generated from databases of fusions found in healthy samples.
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Gene expression as a biomarker in AML 
On a molecular level, the state of a cell is largely characterized by its gene expression. Furthermore, it 
is commonly known that changes in expression of certain genes trigger alterations in the state or 
behavior of a cell. Transcription factors MYC, MYB, FOS and tyrosine kinases ABL1, FES, KIT, PIM play a 
crucial role in hematopoiesis and were the first genes whose expression was studied in AML-derived 
cells60–63. Overexpression of RUNX1, another important transcription factor involved in hematopoiesis, 
enhanced cell proliferation while suppressing granulocytic differentiation64. Increased expression rates 
of growth factor FLT3 were observed in leukemic blasts65 and elevated expression of the CD34 gene in 
leukemic patient samples was associated with lower CR rates and adverse outcome66. Moreover, 
increased expression of WT167, MN168, BAALC69, ERG70, and MECOM71 was shown to be significantly 
correlated with poor prognosis. Besides prognostic relevance, studies have shown that AML subtypes 
can be reliably distinguished based on gene expression72,73. 
In addition to expression analysis by qPCR, microarrays paved the way for simultaneous expression 
analyses of thousands of genes evolving to a popular tool in hematological research throughout the 
first decade of this century. With the advent of NGS, a new milestone in high-throughput screening for 
gene expression was set. Since then, ever more new markers have been identified and gene expression 
profiles have been proven as independent classifiers and prognostic indicators74. Furthermore, several 
studies proposed scoring models based on the expression of gene sets as predictors for therapy 
resistance and survival, providing significant impact for risk assessment75–77. 
A big leap forward in understanding the regulatory mechanisms of a cell was made by the discovery of 
non-coding RNAs (ncRNA). Coding genes comprise only a small fraction of the RNA pool while non-
coding elements constitute over 90% of the processed RNA, playing a central role in the regulation of 
cellular processes78,79. Numerous studies have explored the significance of ncRNAs in different cancers 
but amongst hematopoietic diseases, AML is the most studied entity regarding long ncRNAs (lncRNA)80. 
LncRNA expression profiles have been associated with clinical characteristics, recurrent mutations and 
survival81. Furthermore Schwarzer et al.82 conducted a comprehensive study in order to establish a 
ncRNA expression atlas demonstrating specific signatures for different hematopoietic cell populations. 
For example, the authors identified LINC00173 as a regulator of granulocytic proliferation and 
differentiation. 
Gene expression can be influenced by various factors such as altered methylation of regulatory regions, 
abundance/absence of certain transcription factors, or even chromosomal rearrangements. For 
example, the rearrangement inv(3)(q21q26)/t(3;3)(q21;26) causes the reallocation of a GATA2 
enhancer resulting in overexpression of MECOM and GATA2 haploinsufficiency83,84. In case that a 
chromosomal rearrangement results in a fusion gene (Figure 4), it is expected that the expression of 
the 3' partner gene gets under the control of the 5' partner's promoter. 
10 Introduction 
Thus, extensive gene expression analysis of coding and non-coding genes provides critical information 
with diagnostic relevance and can be easily derived from RNA-seq data. Further expression studies on 
larger cohorts are needed to gain deeper insight into the regulatory mechanism of gene expression 
and the correlation to leukemogenesis, which could lead to the discovery of new drug targets and more 
effective individualized treatment.
Figure 4: Illustration of a fusion gene resulting from a chromosomal rearrangement. Expression of the rear part of Gene B
(3' partner) is supposed to be controlled by the promoter of Gene A (5' partner). 
Objectives 
This thesis is focused on fusion gene detection and gene expression analysis by RNA-seq in the context 
of the application in clinical diagnostics of AML. The specific aims are:
1. Analysis of RNA-seq data from AML patients to measure SMARCA5 expression. Test for correlation 
between gene expression of proliferation biomarker genes and SMARCA5 expression. Test for 
correlation between overall survival of patients and SMARCA5 expression levels.
2. Evaluation of the performance of RNA-seq in fusion gene detection in comparison to methods 
from clinical routine. Analysis of RNA-seq data from cohorts of nearly a thousand AML patients in 
order to identify putative novel fusion genes.
3. Development of a filtering concept integrated into a detection workflow to enable robust 
identification of fusion genes.
11 
Chapter 1 
Loss of ISWI ATPase SMARCA5 (SNF2H) in Acute Myeloid Leukemia Cells Inhibits 
Proliferation and Chromatid Cohesion 
 
Tomas Zikmund, Helena Paszekova, Juraj Kokavec, Paul Kerbs, Shefali Thakur, Tereza Turkova, 
Petra Tauchmanova, Philipp A. Greif, Tomas Stopka 
 
(Int. J. Mol. Sci. 2020, 21(6), 2073; https://doi.org/10.3390/ijms21062073) 
 
In this chapter, we analyzed the relevance of SMARCA5 expression for proliferation of leukemic cells. 
The ATPase SMARCA5 is a member of the imitation switch (ISWI) gene family that are involved in 
chromatin remodeling and play an essential role in DNA repair, transcription, and replication. RNA-seq 
data from AML patients showed significantly elevated SMARCA5 expression in diagnostic samples (high 
amount of immature blast cells) compared to matched remission samples (less than 5% blast cells) 
confirming previous reports of higher SMARCA5 expression in CD34+ AML cells. Moreover, we 
observed shorter overall survival of patients with higher SMARCA5 expression, but this finding was 
statistically not significant. However, we saw a positive correlation of SMARCA5 levels and expression 
of proliferation biomarkers (AURKA, PLK1, CCNA2, CENPF). To examine the effects of SMARCA5 
depletion, SMARCA5 knockout clones were generated from leukemia cell lines (K562, OCI-M2, NB4, 
SKM1, MOLM-13) by CRISPR/Cas9 genome editing. Clones lacking SMARCA5 demonstrated impaired 
proliferation in K562 cells, while knockout clones from other cell lines even seemed not to tolerate 
SMARCA5 depletion at all. Transplantation of SMARCA5 expressing and lacking murine fetal liver cells 
into lethally irradiated mice showed reconstitution of hematopoiesis only in mice that were 
transplanted with SMARCA5 expressing cells, suggesting an essential role in normal blood production 
and implicating that SMARCA5 might play a role in early leukemia-initiating compartments. 
Additionally, SMARCA5 lacking cells were frequently found to have nucleic abnormalities such as 
polyploidy, nucleic budding, karyorrhexis, and multinuclearity. Although decreased cell growth and 
proliferation defects were also observed in healthy non-hematopoietic cells mediated by SMARCA5 
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In this chapter, we collected RNA-seq data of nearly a thousand clinically well-characterized AML 
patients from four different cohorts. We applied two fusion calling methods, namely Arriba and 
FusionCatcher, to identify fusion events and compared detection performance between calls from 
RNA-seq and data from clinical routine diagnostics. Around 90% of fusion genes reported by routine 
were also detected by the RNA-seq methods, while we observed lower sequence read depth in 
samples in which RNA-seq did not detect any fusion despite evidence from routine data. On the other 
hand, we identified 26 known recurrent fusion genes that were not reported by routine diagnostics. In 
general, algorithms for the detection of fusions by RNA-seq tend to report many false positives. 
Therefore, we developed a fusion detection workflow together with several filtering strategies 
including blacklists generated from healthy samples and several metrics assessing evidence levels for 
individual fusion calls. Evidence level cutoffs were derived from known fusion events enabling a 
substantial reduction of putative false positive calls. On average, we detected 51 fusion events per 
patient. Although roughly 70% of these events were excluded by the built-in filters of the callers, the 
number of remaining events indicated a high proportion of false positives. Based on our filtering 
strategies, we excluded approximately 95% of fusion calls that were most likely artifacts. In addition, 
we observed elevated expression of genes in specific cases where they form the 3' end of a fusion 
gene, which can provide further evidence for a fusion event. Finally, we discovered a novel recurrent 
inversion on chromosome 21 resulting in a NRIP1-MIR99AHG fusion transcript which was validated by 
PCR and Nanopore sequencing. Both genes involved in the fusion have already been associated to 
leukemogenesis. Furthermore, we identified 157 putatively novel fusion transcripts with high evidence 
according to our detection workflow. 
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Chapter 3 
A workflow for the detection of robust fusion gene candidates by RNA-seq 
 
This chapter describes the workflow for the detection of fusion genes by RNA-seq and addresses 
filtering approaches to reduce fusion calls that are most likely artifacts. In our study of RNA-seq data 
of 806 AML patient samples (Chapter 2), we observed a high number of reported fusion genes per 
patient, suggesting a high false positive rate of the RNA-seq based tools. The tools provide built-in 
filters such as a minimum number of fusion-supporting reads, annotation-based filtering, internal 
evidence scores and blacklists compiled from public databases of fusions that were found in healthy 
samples. However, the number of fusion genes per patient remained high, even after exclusion of 
fusion genes by the built-in filters (Appendix 2, Figure 2).  
Therefore, we established a filtering pipeline (Figure 5) based on several in-house developed metrics 
in addition to the built-in filters of the fusion callers. First, we included a custom generated blacklist of 
fusion genes that were called by RNA-seq data of 39 healthy samples. Moreover, we observed certain 
genes that are reported in a multitude of different fusion events, which we measured by our 
Promiscuity Score (PS). The assumption is that the higher the PS, the higher the probability for a fusion 
event to be a false positive. In order to test this hypothesis, we compared PS values between known 
and unknown fusion events. Indeed, we observed a maximum PS of 16.5 among known fusions while 
unknown fusions showed significant higher PS values (Appendix 2, Figure S3A). This allowed for the 
definition of distinct cutoffs to filter for fusions resembling observed PS values of known fusion genes. 
Furthermore, we found fusion events consisting of high expressed genes while the respective fusion 
showed only low expression, which might indicate artifacts. In order to assess this discrepancy, we 
captured the relative expression of a fusion by our Fusion Transcript Score (FTS). Known fusions were 
characterized by a median FTS value of 0.35 while unknown fusions showed a median FTS value of 0.1 
(Appendix 2, Figure S3B). This finding allowed for the selection of fusion events resembling higher FTS 
values of known fusions and the exclusion of likely false positive calls characterized by low FTS values. 
Occasionally, we observed that fusion events slip through the FTS filter. Capture of these events was 
addressed by our Robustness Score (RS). Together, these filtering metrics enabled a substantial 
reduction of putative false positive events (Appendix 2, Figure 2) using characteristics of fusion calls 
and estimated gene expression which can also be obtained from RNA-seq data. A detailed description 
of the PS, FTS and RS filter metrics are provided in the following sections. 
Our workflow included two detection streams via Arriba85 and FusionCatcher86. In the final step, only 
overlapping fusion calls from both streams were regarded as robust fusion candidates. Based on the 
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filtering metrics developed in this study, evidence levels were assigned to all identified fusion events, 
which allowed for adjustment of the filter stringency.
Figure 5: Fusion gene detection and filtering workflow. Firstly, fusion calls from Arriba and FusionCatcher are filtered by built-
in filters of the callers. Afterwards, detected fusion events are filtered by a custom blacklist, the Promiscuity Score (PS), the 
Fusion Transcript Score (FTS) and the Robustness Score (RS). Finally, only consistently called fusion events by Arriba and 
FusionCatcher are regarded as robust fusion gene candidates.
Promiscuity Score 
As mentioned in the introduction, certain genes are prone to be detected as part of false fusion events. 
Characteristically, these genes are found to form fusions with many different partner genes. Therefore, 
the PS of a fusion event ( ) measures the average number of different partner genes, that were 
detected in a set of samples, for the two genes involved in that fusion event. In more detail, the average 
number of varying partners, that were detected by Arriba and FusionCatcher for the individual genes 
at the 5' and 3' end of the specific fusion, was defined as . Thus, the PS of a fusion event can be 
formalized as follows: = (  , )= , , ,  {5 , 3 }
, = { , }
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Fusion Transcript Score 
Sequence reads of highly expressed genes are likely to accumulate sequencing errors or produce fusion 
artifacts during the amplification steps. This could result in false mapping and false positive fusion calls. 
It is fair to assume that expression of a fusion correlates to the expression of its partner genes. 
Therefore, we developed the FTS which provides a metric to measure, in transcripts per million (TPM), 
the expression of a fusion relative to the expression of its partner genes: = (  , ) 
 = +    {5 , 3 } 
Calculation of TPM expression requires read counts and the length of the respective gene transcript. 
While these values are available for single transcripts from mapping and gene annotations, this is not 
the case for fusion genes. Due to limited length of the read fragments and the fact that only reads 
covering the fusion breakpoint can be accounted for the expression of the fusion gene transcript, exact 
length and therefore, TPM expression of the fusion transcript cannot be determined. Therefore, TPM 
values for a fusion transcript were approximated by using estimated median insert size of the mapped 
read fragments. 
Robustness Score 
We observed recurrently detected fusion genes being excluded by the FTS filter in most affected 
samples but occasionally passing the filter in a few samples. These fusion genes were characterized by 
a low FTS close to the defined cutoff and an unusual high recurrence among the patients. Most likely, 
these fusion genes represent false positive events. Therefore, we developed the RS which is defined 
as the ratio between the number of samples in which a fusion gene passed the FTS filter and the total 
number of samples in which this fusion gene was called. Only fusion genes passing the FTS filter in at 
least half of the reported samples (RS  0.5) were considered. 
Detection and filtering workflow as a single software package 
Our workflow for fusion gene detection consists of quality filtering, trimming, mapping and insert size 
estimation of the RNA-seq reads, fusion calling, estimation of gene expression and calculation of the 
PS, FTS and RS. These steps require installation of several tools and various packages in the 
computational environment. Therefore, we bundled all software dependencies in a Singularity87 
container and programmatically combined the aforementioned steps into one single analysis. The 
portability of the Singularity software allows for simple execution of our fusion detection workflow on 
different computer systems without the necessity for the installation of further software. The package 
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Discussion 
In the first chapter of this thesis, we analyzed RNA-seq data from large cohorts of AML patients 
focusing on SMARCA5, a gene involved in ATP-dependent chromatin remodeling, and its role in 
leukemic cell proliferation and differentiation. We observed higher expression of SMARCA5 in patient 
samples at the time of diagnosis compared to matched samples at the time of CR, which is consistent 
with a previous study showing upregulation of SMARCA5 in CD34+ AML cells88. Moreover, data 
suggested a trend to shorter overall survival of patients with high SMARCA5 expression. We showed 
that deletion of SMARCA5 reduced cell growth and proliferation of leukemic cells, but also proliferation 
of healthy cells was affected by the absence of SMARCA5. Nevertheless, our findings suggest that 
SMARCA5 could be a potential target for treatment, which needs to be investigated in further studies. 
Although statistically not significant, higher expression of SMARCA5 was associated with shorter 
survival, which is consistent with previous studies in solid tumors reporting correlation of high 
SMARCA5 expression with disease aggressiveness and resistance to chemotherapy89,90. Our findings 
suggest that SMARCA5 expression rates should be taken into consideration for the prognosis and 
treatment of AML patients. Furthermore, aberrant expression of certain genes can provide evidence 
for fusion events, as will be discussed in the following section. 
 
In chapter 2, we studied RNA-seq data derived from bone marrow or peripheral blood samples of 
nearly a thousand well-characterized AML patients. To evaluate the performance of RNA-seq regarding 
the detection of fusion genes, we defined a benchmark of true fusions that were reported by clinical 
routine diagnostics. RNA-seq based methods showed high sensitivity by detecting 90% of the true 
fusion set and the identification of a relevant number (n=26) of recurrent AML-related fusion genes 
that were not reported by routine diagnostics. This demonstrates the strong potential of RNA-seq for 
complementary application in clinical diagnostics of AML. In most cases in which true fusions were 
missed by RNA-seq, affected samples showed overall lower read coverage, especially at the loci of 
genes involved in known recurrent fusions. Although sequencing depth of these samples (~30 mio. 
reads) is sufficient for overall analysis of gene expression, transcript discovery (e.g., fusion gene 
transcripts) requires higher sequencing depth, according to the data standards of the ENCODE 
consortium91. Thus, fusion gene detection might have been impaired by lower sequencing depth of 
these samples. Furthermore, 71% of samples in which no true fusion could be detected by RNA-seq 
were from the same cohort, indicating cohort-specific sequencing issues. 
In the effort to identify novel fusion genes, we developed a detection workflow including several 
filtering steps, which allowed for substantial reduction of reported fusion genes that are most likely 
artifacts. In addition to our filtering strategies, we showed that gene expression alone could already 
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provide evidence for certain fusion events. As described in the introduction, expression of the partner 
gene at the 3' end of a fusion is supposedly controlled by the promoter of the partner gene at the 5' 
end. Therefore, it is expected that expression of the 3' partner gene should adjust to expression levels 
of the 5' partner. Especially in cases in which the 3' partner is usually not expressed or expressed at 
low levels, the 3' partner should show increased expression. Indeed, we observed this effect in cases 
of known recurrent fusion genes as well as in cases of novel fusion candidates. 
Based on our detection workflow, we identified 157 novel fusion gene candidates. The most interesting 
fusion gene among those candidates was NRIP1-MIR99AHG, resulting from inv(21)(q11.2;q21.1) and 
recurrently found in nine patients. Based on available cDNA and gDNA of some patient samples, we 
validated the NRIP1-MIR99AHG rearrangement by PCR and Nanopore sequencing. Long reads from 
Nanopore sequencing revealed several distinct NRIP1-MIR99AHG fusion transcripts. None of these 
transcripts included an annotated open reading frame suggesting no resulting protein products. One 
of the fusion breakpoints is located upstream of MIR125B2 which belongs to the miR-99a/let-7c/miR-
125b-2 tricistronic gene cluster residing in an intronic region of MIR99AHG. This miRNA cluster was 
shown to play a role in homeostasis of hematopoietic stem and progenitor cells92, and therefore, 
disruption of this cluster caused by the NRIP1-MIR99AHG rearrangement might contribute to 
leukemogenesis. Furthermore, overexpression of MIR99AHG was shown to increase proliferation in 
acute megakaryoblastic leukemia cell lines93. In hematopoietic cells, MIR99AHG is usually not 
expressed or expressed at low levels only. We demonstrated that the NRIP1-MIR99AHG fusion drives 
transcription of the 3' end of MIR99AHG, which might also be a factor in leukemogenesis. However, 
disruption of NRIP1 might also play a role since it was found to be involved in other fusions94,95 and has 
been linked to hematological malignancies in previous studies96,97. Further studies are needed to 
untangle the mechanism and determine the clinical implications of this novel recurrent rearrangement 
in AML and other hematological entities.  
 
The presented workflow for the detection of fusion genes by RNA-seq (Chapter 3) includes several 
computational tools and filtering metrics which were developed in this study. Implementation of these 
tools requires preceding installation steps and the resolution of software dependencies. This can be 
troublesome and might lead to conflicts within certain system environments. Therefore, a software 
package was developed including all steps of the workflow which were programmatically bundled into 
a streamlined and easy-to-use pipeline for reproducibility and robust fusion gene analyses. 
The main feature of this workflow was the filtering procedure for reducing the number of false positive 
fusion calls and included: (1) Built-in filters of the callers, (2) Custom fusion blacklist, (3) PS filter, (4) 
FTS filter, (5) RS filter, (6) Consistently called fusion genes between Arriba and FusionCatcher. The 
fusion callers already provide simple filters such as blacklists, fusion supporting reads or annotation-
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based filtering, etc. However, even after utilization of these filters many fusion events per patient were 
reported indicating a high proportion of false positive calls. The built-in blacklists of the callers are 
compiled from public databases and might therefore not be complete. We showed that an additional 
blacklist, generated by fusion gene detection in publicly available healthy samples, can further reduce 
irrelevant fusion events. In order to filter for robust fusion candidates, we excluded further events 
based on evidence levels derived from three in-house developed metrics i.e., PS, FTS and RS. These 
metrics are based on gene expression measurements and frequencies of called fusion genes, data that 
are concurrently retrieved in the fusion detection process. We observed distinctive differences 
between known and unknown fusion events that were evaluated by these metrics, which allowed for 
differentiation of likely real fusions and fusions with a high probability of being an artifact. 
The PS of a fusion gene measures how frequent the respective partner genes were found to be involved 
in other fusion events. Events with high PS are likely artifacts and cutoffs were defined based on PS of 
known fusion genes. It must be noted that PS values strongly depend on sample size. The more samples 
are used to estimate PS, the better the estimation gets, enabling more accurate differentiation 
between true and false fusion events. Moreover, different sequencing procedures (e.g., library 
preparation kit, sequencing platform, sequencing depth) or different detection algorithms have impact 
on fusion calling. Therefore, application of the PS filter will perform best on uniformly called fusion 
events in uniformly sequenced cohorts comprising a proper number of samples. 
Furthermore, our FTS estimates the expression of a fusion event (based on breakpoint spanning reads) 
in relation to the expression of the respective partner genes (excluding breakpoint spanning reads). 
The underlying assumption is that a relatively low number of fusion-supporting reads compared to the 
number of reads supporting the individual partner genes (low FTS) is an indicator for fusion artifacts. 
However, considering that RNA-seq data is usually generated from a mixed cell population, real fusion 
genes might also be characterized by a low FTS since they might reside in small subclones only. 
Nevertheless, comparative analysis of FTS values between known and unknown fusion events provided 
an indicative cutoff for maximizing specificity while maintaining sensitivity. 
Finally, we included our RS as another quality feature for fusion calls. We noticed that in some cases 
certain fusion genes get past the FTS filter while the same fusion gene, detected in many other 
samples, gets filtered out. This might be explained by one of the two following reasons: (I) The fusion 
gene is present only in a very small subclone, so that expression of this fusion is usually too low to pass 
the FTS filter, but in some patients this fusion gene happens to show enough expression (e.g., present 
in larger clones) for reaching the FTS cutoff. (II) Under certain conditions, fusion-supporting read 
artifacts mimic sufficient expression to pass the FTS filter. In either case, the identified fusion event 
does not provide sufficient relevance to be considered as a robust candidate. 
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Taken together, our filtering workflow provided a well-founded procedure for the exclusion of putative 
false positive fusion events that were detected by current RNA-seq methods. This was supported by 
our study of nearly a thousand AML patients (Chapter 2) presenting the discovery of a novel recurrent 
fusion gene and further robust fusion candidates.
Conclusion 
RNA-seq is a powerful tool for fusion gene detection and concurrent measurement of gene expression. 
Detection performance was shown to be influenced by sequencing properties such as sequencing 
depth or protocol. Furthermore, a high number of fusion calls reported by current detection algorithms 
are artifacts and careful filtering is required for robust fusion gene identification. Therefore, we 
developed a fusion detection workflow with integrated filtering strategies and identified many 
clinically relevant fusion genes that were not reported by routine diagnostics. We showed that RNA-
seq constitutes a valuable complementary tool in clinical diagnostics for reliable transcriptome-wide 
identification of fusion genes and comprehensive gene expression analysis. Moreover, RNA-seq has 
the potential to discover novel fusion events painting a more complete picture of the genetic landscape 
in malignancy, which we demonstrated by the detection of NRIP1-MIR99AHG, a novel recurrent fusion 
gene in AML resulting from an inversion of chromosome 21. 
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Abstract: ISWI chromatin remodeling ATPase SMARCA5 (SNF2H) is a well-known factor for its
role in regulation of DNA access via nucleosome sliding and assembly. SMARCA5 transcriptionally
inhibits the myeloid master regulator PU.1. Upregulation of SMARCA5 was previously observed
in CD34+ hematopoietic progenitors of acute myeloid leukemia (AML) patients. Since high levels
of SMARCA5 are necessary for intensive cell proliferation and cell cycle progression of developing
hematopoietic stem and progenitor cells in mice, we reasoned that removal of SMARCA5 enzymatic
activity could affect the cycling or undifferentiated state of leukemic progenitor-like clones. Indeed,
we observed that CRISPR/cas9-mediated SMARCA5 knockout in AML cell lines (S5KO) inhibited
the cell cycle progression. We also observed that the SMARCA5 deletion induced karyorrhexis and
nuclear budding as well as increased the ploidy, indicating its role in mitotic division of AML cells.
The cytogenetic analysis of S5KO cells revealed the premature chromatid separation. We conclude
that deleting SMARCA5 in AML blocks leukemic proliferation and chromatid cohesion.
Keywords: SMARCA5; SNF2H; AML; leukemia; CRISPR; therapeutic target
1. Introduction
Acute myeloid leukemia (AML) is a malignant hematopoietic disease derived from myeloid-primed
stem cells resulting in accumulation of myeloid blasts. AML patients have a poor prognosis and
the only known efficient therapy is bone marrow transplantation combined with chemotherapy.
Next-generation sequencing revealed that despite similar cytology and cellular features, the mutational
profile of AML clones can be very heterogenic. Leukemogenesis involves multiple types of genomic
alterations from single nucleotide variants to large chromosomal abnormalities (involving deletions,
translocations, or chromosomal gains and losses). Targets of mutagenesis are often genes encoding
regulators of gene transcription (e.g., RUNX1, CEBPA, GATA2), DNA methylation (e.g., DNMT3A,
IDH1, IDH2), and genome organization (e.g., CTCF, RAD21, SMC3).
Immature cells during tissue development require ATP-dependent chromatin remodeling activities
to ensure accession of regulatory proteins to DNA in order to control replication, transcription, or DNA
repair. Activities that facilitate nucleosome spacing and assembly during tissue development are
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provided mainly by evolutionary conserved Swi2/Snf2 family helicases. Smarca5 (also known as Snf2h)
belongs to important enzymes of the Swi2/Snf2 family with remodeling activity that is required for
successful hematopoietic development in mammals [1–3]. In mouse, Smarca5 represents the catalytic
subunit of ISWI remodeling complexes that is indispensable for developing embryo and later for
fetal hematopoiesis [1,2]. Interestingly, Smarca5 loss was accompanied by upregulation of p53 and of
its transcriptional targets that are usually linked to the induction of apoptosis in response to DNA
damage (e.g., p21/Cdkn1a, Noxa/Pmaip1, and Bax) [1]. Our work and the work of others suggested that
Smarca5 not only facilitates proliferation-associated events but also helps to activate transcriptional
programs of particular developmental stages to set proper expression identity of immature cells [4,5].
Additional evidence implicated that Smarca5 regulates global gene expression programs and function
of many human gene regulatory elements by cooperating with CTCF [6–8].
Smarca5 represents an integral part of heterodimeric ISWI complexes that contain usually
a bromodomain-containing protein (BAZ1A, BAZ1B, BAZ2A, BAZ2B). ISWI complexes were originally
identified in Drosophila but later they were discovered also in humans, namely, NURF (ATPase motor
of the nucleosome remodeling factor), ACF (ATP-utilizing chromatin assembly and remodeling factor),
and CHRAC (chromatin assembly complex). Later, additional human complexes were found, such
as RSF, NoRC, WICH, CERF, and finally, SNF2H-cohesin [9]. Most ISWI complexes are involved in
regulating cell cycle progression albeit via different mechanisms. While many ISWI complexes regulate
transcription by nucleosome sliding mechanism utilizing either RNA-Polymerase 1 (RNAP1) (NoRC,
B-WICH) or RNAP2 (ACF, NURF, CERF, WINAC), other complexes are linked to replication/repair
(CHRAC, WICH) or chromatid cohesion (SNF2H-cohesin) [10]. It appears that SMARCA5 plays
an indispensable part in the ISWI complexes (albeit it can remodel chromatin alone in acellular systems);
however, in certain situations, it may be replaced within ISWI complexes by its close homologue
SMARCA1 (SNF2L) as shown in rather differentiated cells of the cerebellum [4].
Currently, over 20% of all malignancies carry mutations in one of the subunits of chromatin
remodeling complexes of the SWI/SNF family (see [11,12]). These mutations often decrease protein
stability and cause loss of the particular subunit, which leads to the assembly of incomplete
remodeling complexes with different functions in vivo and altered capability to precisely regulate
gene expression [13]. In the case of the ISWI subfamily, the mutations of various ISWI subunits
identified in oncologic diseases have still yet unknown impact on tumorigenesis. In solid tumors the
overexpression of SMARCA5 [14–18] has been associated with disease aggressiveness, chemoresistance
and proliferation activity [7]. SMARCA5 expression was found dysregulated in many human malignant
tumors, such as aggressive gastric cancer, breast cancer, or prostate cancer. In addition, the SMARCA5
gene is a target of cancer-associating miRNA regulation [14–18]. SMARCA5 overexpression has
been also observed in AML CD34+ progenitors [7,19]. SMARCA5, through the interaction with
CTCF in leukemic cells, actively inhibits expression of the SPI1/PU.1 gene [7] that represents key
hematopoietic transcription factor and dose-dependent leukemia suppressor [20]. Additional work
utilizing the CRISPR/Cas9 genome editing in vitro revealed that among hematopoietic cancer cell
lines, those derived from AML patients were the most SMARCA5 dependent [21]. We herein studied
the consequences of SMARCA5 deletion in AML cells and showed that SMARCA5 targeting affected
proliferation and resulted in chromosomal aberrations and polyploidy pointing to the role of SMARCA5
in mitotic division. We believe that delineating the effects of SMARCA5 targeting might pave the way
for new approaches in the therapy of AML.
2. Results
2.1. SMARCA5 Overexpression Marks the Hyperproliferation and Cytogenetically Abnormal AML Patients
Based on previous evidence documenting SMARCA5 overexpression in small AML patient
subset [19], we examined RNAseq data of bone marrow samples from AML patients with recorded
overall survival (OS). We confirmed our previous observation [19] that SMARCA5 levels are significantly
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elevated at the time of diagnosis and decreased after the patients achieved complete hematologic
remission (Figure 1A). We next associated SMARCA5 expression and clinical parameters and (due
to genetic AML heterogeneity) followed separately cytogenetically normal (CN) and abnormal (CX)
AML patients. Hence, we could observe a trend for decreased OS in the AML patient population with
higher SMARCA5 expression and carrying cytogenetic abnormalities (Figure 1B). We also observed
that higher SMARCA5 levels correlated with mRNA expression of proliferation biomarkers such as
AURKA, PLK1, CCNA2, CENPF (Figure 1C).
Figure 1. (A) SMARCA5 expression of matched AML samples at the time of diagnosis (Dx) and
complete remission (CR). Dots represent individual samples; dashed lines connect matched patient
samples. Boxes: distribution of the Dx and CR groups; intermediate line =median. Significance was
estimated using a paired Wilcoxon test. (B) Survival analysis of AML patients divided into quartiles
(from low Q1 to high Q4; Q1: 0–25% +Q2: 25–50% +Q3: 50–75% vs. Q4: 75–100%) based on SMARCA5
mRNA levels (cn: cytogenetically normal, cx: cytogenetic abnormalities). (C) Correlation of mRNA
levels of PLK1, AURKA, CCNA2, CENPF, and SMARCA5 (R2 and p-value indicated).
2.2. SMARCA5 Deletion Inhibits AML Cell Proliferation
To test requirement of SMARCA5 for AML cell growth, we produced a null allele using
CRIPSR/Cas9 genome editing technology (Figure 2A). Targeted was exon5, which codes a portion of
evolutionarily conserved ATPase domain and that was previously shown to be a targetable region
using the Cre-loxP1 system. Deletion of exon5 results in a frame shift mutation disabling expression
of Smarca5 protein in mouse [1]. For the experiments, human K562 cells (AML M6 subtype) were
initially utilized as they were previously used for antisense oligonucleotide-mediated transient
knockdown of SMARCA5 [2]. K562 cells were transfected by a pair of pX330-mVenus vectors
containing sgRNAs complementary to a sequence in the SMARCA5 introns 4 & 5 and the the effect of
CRISPR/Cas9-mediated deletion of exon5 was tested by PCR. Analysis of fragments amplified from
genomic DNA of FACS-sorted mVenus-positive clonal populations identified 5 clones (#H10, D7, H4,
E7, H7) with a single shortened PCR product (~632bp compared to 1175bp in controls) that were
homozygously mutated (Figure 2B). Sanger sequencing of PCR products confirmed that clones H10, D7,
E7, and H5 contained the same deletion (543bp) and clone H4 an even larger deletion (582bp) within
SMARCA5 exon5 (Figure 2C). In addition, quantitative PCR and Western blot analyses of the cellular
extracts confirmed that the Cas9-mediated deletion of the SMARCA5 gene resulted in loss of SMARCA5
expression (Figure 2D,E). The resulting subclones had no expression of vector-coded & episomally
expressed Cas9 nuclease. In addition, eight predicted off-target candidates (SRGAP2, RNF17, PRG4,
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GYPA, POLQ, CYB5R4, BCKDHB, NAV2) had no alteration of their sequences. Thus, we managed
to effectively delete SMARCA5 in the K562 subclones to create a cellular model for studying how
SMARCA5 loss affected AML cell growth.
Figure 2. Inactivation of SMARCA5 gene expression (S5KO) in AML cells. (A) Scheme of generating the
S5KO using CRISPR/Cas9 technology. The Cas9 nuclease was targeted into two intronic sites (scissors)
surrounding exon5 of the SMARCA5 gene. The sequences of guide RNAs are depicted in gray boxes
on the right. Indicated are exons 4-6 (small rectangles) and genotyping primers (blue arrowheads).
(B) PCR verification of the exon5 deletion in the indicated S5KO clones. (C) Analysis of SMARCA5
gene region following the Cas9 nuclease deletion. PCR products (same as in B) were Sanger-sequenced
and aligned with the wt sequence using the Kalign web tool. After sequencing, the precise length of
the resultant PCR amplified region was determined (on the left in brackets). (D) Quantitative PCR
analysis of SMARCA5 mRNA expression in the S5KO clones (n = 5) compared to controls (n = 10).
Data normalized to the GAPDH mRNA. Student’s t-test, p < 0.00001 ****. (E) Immunoblotting of
SMARCA5 expression in CRISPR/Cas9-treated K562 or controls. β-actin controlled the load.
2.3. Smarca5 Deletion Inhibits Proliferation of Myeloblasts and Affects Function of Normal Stem Cells
To characterize the effect of SMARCA5 deletion in the AML-S5KO subclones, we monitored their
growth in culture by the WST-1 assay correlating the number of metabolically active cells in the 72-hr
culture within a 96-well plate. We quantitated the data with a scanning multiwell spectrophotometer
(ELISA reader) (Figure 3A, upper panel) and also in parallel counted the viable cells with an automated
cell counter (Figure 3A, lower panel). We observed that starting day 1, the S5KO subclones produced
less formazan product/s compared to AML ‘control’ cells, indicating that loss of SMARCA5 impaired
proliferation of leukemic cells. We also attempted to create S5KO clones from additional AML cell lines.
We repeatedly used OCI-M2, NB4, SKM1, MOLM-13, however, despite the fact that these AML cell lines
grew normally in tissue culture conditions, the recombined cells by pX330-mVenus vectors followed
by the single cell sorting could not produce clones with exon5 deletion. We therefore used the method
of serial dilution of transfected cells. This approach, in contrast to the previous approach, produced
populations of OCI-M2 and SKM1 cell lines with detectable Cas9-edited SMARCA5 loci. However,
the signals of mutated alleles markedly decreased during long-term cultivation, suggesting that the
S5KO cells were overgrown by cells containing at least one intact SMARCA5 allele. Thus, the deletion
of the SMARCA5 gene completely impaired leukemic cell proliferation in most of the AML cell lines,
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while in K562 cells it was tolerated albeit under markedly lower proliferation activity, which allowed
us to study it in more detail.
Figure 3. Proliferation of AML and progenitor cells upon Smarca5 gene deletion. (A) Proliferation of
S5KO clone #D7 and control cells analyzed by WST-1 assay. Mean ± SEM of formazan absorbance (top)
and cell count (bottom) (pentaplicates). Student’s t-test, p < 0.05 *, p < 0.01 **. (B) Flow cytometry
analysis of donor (CD45.2) and host (CD45.1) derived hematopoietic cells at 14 days following
the transplantation of donor fetal liver cells into lethally (7.5 Gy) irradiated host animals. Donor
(red trapezoid) and host-derived (black rectangles) bone marrow cells (upper dot plots) and splenocytes
(lower dot plots) were distinguished by the expression of yellow fluorescent protein (eYFP) or surface
variant of CD45. Control mice: Smarca5fl/+ Vav1iCre R26eYFP; Smarca5 mutant mice: Smarca5fl/fl
Vav1iCre R26eYFP. Data are representative of repeated experiments.
AML cell population resembles early hematopoietic progenitors. Thus, as controls to AML
cells, we studied early murine blood progenitors. Previously it was shown that Smarca5 loss in
mouse partially inhibits differentiation of early Lin−Sca-1+c-Kit+ hematopoietic progenitors [1]. To test
whether Smarca5 deletion affects reconstitution of early blood progenitors after transplanting them
into normal murine recipients, we utilized the hematopoietic reconstitution assay. We transferred
E13.5 mouse fetal liver cells (C57Bl/6J Ly5.2 background) isolated either from control Smarca5flox/+
Rosa26eYFP/+ Vav1-iCRE or Smarca5-deficient (Smarca5flox/− Rosa26eYFP/+ Vav1-iCRE) embryos into
lethally irradiated adult C57Bl/6J Ly5.1 recipients. Flow cytometric analyses of bone marrow and
spleen at several weeks after transplantation revealed that repopulation was detected only in animals
transplanted with cells in which the Smarca5 gene was preserved. Thus, homeostatic expression of
Smarca5 is very important for hematopoietic reconstitution (Figure 3B), implicating a possibility that
the Smarca5 role in AML cells might also involve a very early leukemia-initiating compartment.
2.4. Inactivation of Smarca5 Causes Nuclear Abnormalities and Polyploidy
To gain insight into the subcellular structures of the AML S5KO cells, we utilized hematology
staining using a standardized May–Grunwald and Giemsa–Romanowski stain procedure. As indicated
within Figure 4A, the control AML cells were represented by a uniform layer of myeloblasts with large
round nuclei, fine chromatin structure, and prominent nucleoli. Significantly more frequent nuclear
abnormalities were observed in the S5KO cells compared to controls. These included nuclear budding,
internuclear bridging, karyorrhexis, and multinuclearity seen in 10% to 65% of all analyzed cells
(Figure 4B). To study effect/s of S5 depletion in nonhematopoietic cells, we derived mouse embryonic
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fibroblast (MEF) with Tamoxifen-regulated Cre-recombinase activity (Cre-Esr1) from Smarca5fl/fl Trp53−/−
animals. Trp53-mutated MEFs were chosen because of their lower propensity to enter proliferation
senescence and because most AML cell lines including K562 have TP53 gene inactivation [22]. After
6 h incubation with 100 nM 4-hydroxy-tamoxifen (4OHT) and additional 90 h of culture, the MEF
cells were depleted from Smarca5 protein (Figure 4C). Decrease of Smarca5 protein level negatively
influenced the cell growth and the proliferation defect had already occurred within 40 h from the start
of the 4OHT treatment while 4OHT untreated and control Cre-Esr1 lacking cells proliferated normally
(Figure 4D). This proliferative defect resembled one observed in AML S5KO clones. The flow cytometry
analysis revealed that aberrant proliferation was accompanied by lower proportion of S-progressing
and mitotic (pH3S10+) cells. In addition, we noted a higher number of cells with polyploid nuclei
(Figure 4E) that was concomitant to a decreased proportion of diploid cells upon S5 deficiency in MEFs.
Taken together, inactivation of SMARCA5 triggers a cell proliferation blockade and results in nuclear
abnormalities of exceedingly cycling leukemic as well as normal hematopoietic cells.
Figure 4. Nuclear abnormalities in S5KO cells. (A) Cytology of control (left) and S5KO clone #D7
(right), nuclear abnormalities indicated and shown (B) as mean % ± Stdev of control, 400 cells/subclone
analyzed. Student’s t-test, p < 0.05 *, p < 0.01 **, p < 0.0001 ****. (C) Immunoblotting of Smarca5: MEF
cell lines (Smarca5fl/fl Cre-Esr1: untreated, 4OHT-treated (100 nM, 6 h exposure, 4 days of culture).
β-actin = loading control. (D) IncuCyte cell proliferation analysis; control Smarca5fl/fl (upper panel)
vs. Smarca5fl/fl Cre-Esr1 (lower panel) MEFs in absence/presence of 4OHT (100 nM, 6 h exposure),
or alternatively, 4OHT was added 72 h prior to IncuCyte monitoring (4OHT—72 h). Y-axis: mean
confluency (%) and ± Stdev of at least 16 different regions of the cultivation plate, X-axis: time (h).
(E) Flow cytometry analysis of control and Smarca5fl/fl Cre-Esr1 MEF population cell cycle progression
using EdU/DAPI double staining (upper dot plots). Black rectangles depict all S-phase and non-S-phase
cells with different ploidy (2N-16N). Histograms show percentage of phospho-histone H3 (Ser10)
positive mitotic events in experimental cell lines. (D) and (E) represent biological triplicates.
2.5. Cytogenetic Abnormalities and Gene Expression Dysregulation in the S5KO AML Cells
As pointed out in the Introduction section, SMARCA5 protein was previously shown to load
cohesin complex onto human chromosomes [23]. As the canonical role of cohesin is the sister chromatid
cohesion, we next analyzed the structures of mitotic chromosomes in the AML S5KO cells on metaphase
spreads. The analysis of the S5KO subclone D7 consistently showed (Figure 5A) that among other
chromosomal abnormalities, the cohesion defects were by far the most frequent involving premature
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chromatid separation and loss of cohesion. Compared to the controls that contained only 12%, the S5KO
mitotic cells displayed defects in chromatin cohesion in 70% of all cases. Similarly, the defects of
chromatid cohesion were seen also in MEF cell-derived mitotic chromosome spreads (Figure 5B,C).
These data suggest that SMARCA5 inhibition affects cohesin function in general.
Figure 5. SMARCA5 loss causes karyotypic changes in K562 cells. (A,B) Mitotic chromosome analysis
of S5KO cells vs control K562 cells (clone #D7, (A)) or MEF cells (B). 1000X magnification. (C) Table
summarizes all chromosomal aberrations; data from technical triplicates, for each replicate a total of
100 mitotic nuclei were counted. Mean percentage of chromosomal abnormalities with Stdev, Student’s
t-test, p < 0.05 *. (D) Computational analysis of correlations between expression of SPI1/PU.1 and
SMARCA5 in samples of adult AML patient samples; for details, see Materials and Methods section.
(E) Quantitative PCR analysis of SPI1, CSF1R, MYB, GATA1, and CBFB mRNAs expression in the S5KO
clones (n = 5) compared to controls (n = 7). Data were normalized to the GAPDH mRNA. Student’s
t-test, p < 0.05 *, p < 0.001 **.
In order to better understand the cooperative nature of SMARCA5 and its interacting partners
in AML, we correlated their expression using RNAseq data in AML patients. Hence, significant
association exists between the expression pattern of SMARCA5 and BAZ proteins (BAZ1A, BAZ1B,
BAZ2A, BAZ2B) as well as the members of the CTCF/cohesin complex across human AML samples.
This implicates, albeit indirectly, a role of SMARCA5 in CTCF/cohesin function in AML that also
coincides with karyotype abnormalities imposed by a SMARCA5 loss.
We recently showed that SMARCA5 (together with the CTCF/cohesin complex) represses
PU.1-mediated myeloid differentiation [7] and similarly, we noted that SMARCA5 regulates
GATA1-mediated erythropoiesis [1]. We therefore next decided to analyze the levels of SPI1/PU.1
and GATA-1 transcripts with respect to SMARCA5. As expected, transcriptomic data from AML
Cooperative Group München (Figure 5D) showed an inverse correlation between SPI1/PU.1 and
SMARCA5 expression in AML patient samples. To further assess the role of SMARCA5 in regulation
of the hematopoietic transcription program, we determined the expression of a set of selected mRNAs
upon the genetic ablation of the SMARCA5 gene in K562 cells. Compared with previously published
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data documenting an inverse relationship between SMARCA5 and hematopoietic transcription factors
PU.1 or GATA-1, we observed that upon SMARCA5 deletion in K562 cells the level of SPI1/PU.1
and some of its targets (CSF1R) became downregulated while other transcription factors (GATA1,
CBFB) were upregulated. The dysregulation of mRNA pattern of SMARCA5 targets upon SMARCA5
deletion can be attributed to the heterogeneity of the AML cell lines and also possibly to multiple
genetic/cytogenetic abnormalities imposed by the SMARCA5 loss.
3. Discussion
We herein studied how ISWI ATPase SMARCA5/SNF2H controls in AML the proliferation and
gene expression of myeloblasts as SMARCA5 appeared to be an interesting target for anti-AML therapy.
Our previous work demonstrated a pattern of SMARCA5 upregulation at AML diagnosis followed
by its normalization upon achieving the hematologic remission. Importantly, additional work has
not identified recurrent mutations of SMARCA5 in AML or any malignant disease (so far analyzed
by next-generation sequencing-based techniques). For example, for the SMARCA5 gene, only 186
variants with an amino acid residue substitution exist in nearly ~20 thousand oncologic patients (<1%).
There also exist infrequently the variants in ISWI-interacting BAZ proteins detected in cancer, however,
the significance of these variants remains also unknown. Importantly, among the AML-associated
variants, only the SMARCA5-interacting proteins, CTCF and members of the cohesin complex, were
shown consistently mutated in AML [24]. Based on this, we expected SMARCA5 indispensability
for AML proliferation and its levels possibly reflecting the proliferative nature of AML cells. Indeed,
the RNAseq analysis of a large set of AML patients confirmed that AML cells overexpressed SMARCA5
and its levels correlated with many ISWI-complex members including also cohesin complex, and finally,
that the proliferative nature of AML cells marked by upregulation of SMARCA5 was supported by
a trend in shorter OS albeit only in those AML patients that were marked by cytogenetic aberrations
(see Figure 1).
Upon targeting of the SMARCA5 gene in AML cell lines with a CRISPR/Cas9-mediated deletion
strategy, we could observe that AML cells lacking SMARCA5 markedly slowed the proliferation rate
and became dysplastic with multiple karyotypic abnormalities. Inhibiting SMARCA5 to achieve
suppression of AML growth may be thus a very efficient strategy as AML cells that are likely addicted
to SMARCA5 in order to overcome various chromatin obstacles such as complex karyotype or also
polyploidy often seen during progression of AML. Other data further implicated that SMARCA5 is
very important also at the stem cell level to regulate their innate function: to repopulate the progeny.
Indeed (as shown by Figure 3), repopulation activities were greatly reduced in normal hematopoietic
stem cells in which the Smarca5 gene was genetically deleted. Our observation, however, does not
rule out the possibility of SMARCA5 being an AML target as i) the AML cells are highly proliferating
compared to their normal counterparts, and ii) SMARCA5 being expressed in stem cells implicates
that antiSMARCA5 therapy would preferentially target the leukemia stem and progenitor cells.
While SMARCA5 expression represents a potential target for AML therapy, it may also serve
as a factor of therapeutic resistance in AML. It is likely that additional factors will be involved in
modulating therapy efficacy using SMARCA5 inhibitors in the future. As the Smarca5 loss was sensed
in a mouse model by a) increased p53 levels and b) associated with DNA damage response (DDR),
and c) activation of the p53 targets [1], very likely the tumor cells with DDR sensing defect would have
a higher propensity to tolerate SMARCA5 level downregulation. This notion is supported by our other
study demonstrating that proliferation defect imposed by Smarca5 deficiency can be partly restored
with concomitant Trp53 deletion in murine thymocytes [3].
Our herein presented data indicate that AML growth is dependent on the expression of chromatin
remodeling protein SMARCA5 that is a known partner of AML-associated targets: cohesin complex
and CTCF [23]. Data presented in Figures 4 and 5 implicate that proliferation inhibition upon
SMARCA5 targeting is at least in part caused by karyotype abnormalities, especially cohesion defects,
and possibly also by a putative replication defect due to defective chromatin compaction as well as
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dysregulation of gene expression pattern of the key hematopoietic lineage restricted transcription
factors. Interestingly, the nuclear changes after S5 deletion such as polyploidy were also described
in other cell lines of hematologic origin [1,3] but not as a result of Smarca5 deletion of developing
brain or eye lens [4,5]. Similar evidence was noted upon experimental manipulation with cohesin
complex members; for example, the nonsense mutations in STAG2 (generated in the THP1 AML
cell line) led to defects in sister chromatid cohesion and induced anaphase defects, which resulted
in proliferation blockade [25]. Important connections between replication and cohesion have been
established in the HeLa tumor cells, in which the interfering with replication affected chromatid
cohesion and caused a defect in mitotic progression [26]. Others suggested that cohesion defects
depend on a functional mitotic spindle checkpoint in regulating mitotic progression [27]. It seems that
the strategy of inhibiting SMARCA5 in AML to block leukemogenesis becomes even more vital as
shown recently using inhibitors of SMARCA5 (ED2-AD101) that target the HELICc-DExx domain to
release the terminal AML cells into differentiation while sparing normal hematopoiesis in preclinical
animal models [28]. Our work also suggests that upon inhibiting SMARCA5-mediated proliferation of
AML cells, we also can face the problem of inhibiting proliferation of normal cells. Further work in
this respect on experimental animals is under way. An additional strategy to inhibit AML cell growth
specifically could be to target the SMARCA5 exon5 in AML cells by CRISPR/Cas9 as evidenced by
the herein presented data. Data from global CRISPR/Cas9 screen identified that SMARCA5 targeting
was very efficient and caused cell growth inhibition in several additional AML cell lines (OCI-AML2,
OCI-AML3) and also in lymphoma and carcinoma cell lines [21]. Together, our as well as others’ data
demonstrate that SMARCA5 is a valuable epigenetic target suitable for inhibitor discovery projects
and subsequent validation in MDS/AML and potentially also in other types of cancer.
4. Materials and Methods
4.1. CRISPR Vector Design
pX330-Venus (kindly provided by Dr. Bjoern Schuster) produces CRISPR/Cas9 enzyme
that cleaves at a specific location based on sequence guide sgRNA defined target
sequences in SMARCA5 intron4 (5′-TTCTTACGTTACCCATATACTGG-3′) and SMARCA5 intron5
(5′-ATTTATCATATTTTCAGCGATGG-3′). CRISPR/Cas9 enzyme is also fused with fluorescent protein
mVenus, that enables selection of successfully transfected clones by FACS sorting. The DNA sequences
for the sgRNA SMARCA5 intron4 and sgRNA SMARCA5 intron5 were synthesized by Sigma-Aldrich
as four oligonucleotides with modifications at position 1 (to encode a Guanine due to the transcription
initiation requirement of the human U6 promoter). These two pairs of complementary oligos were mixed
together, boiled at 95 ◦C for 10 min, and allowed to cool down to RT to hybridize. Double-stranded
oligos also designed with complementary BbsI overhangs on 3′ and 5′ ends were ligated into BbsI
linearized pX330-Venus vector using T4 Ligase enzyme (Thermo Fisher Scientific, Waltham, MA, USA).
Ligation mixtures were transformed into Subcloning Efficiency DH5α Competent Cells (Invitrogen,
Carlsbad, CA, USA) following the manufacturer’s protocol. pX330-Venus sgRNA hSMARCA5
intron4 and pX330-Venus sgRNA hSMARCA5 intron5 were isolated and purified by GenElute HP
Plasmid Midiprep kit (Sigma-Aldrich, St. Louis, MO, USA) and correct oligo insertion verified by
Sanger sequencing.
4.2. Cell Lines
K562 cells (ATCC, Manassas, Virginia, USA) were cultured in 90% Iscove’s Modified Dulbecco’s
Medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. NB4, SKM-1,
and MOLM-13 were cultured in 90% RPMI-1640 medium (Sigma-Aldrich), OCI-M2 in 80% Iscove’s
Modified Dulbecco’s medium (Biosera, Kansas City, MO, USA) at 37 ◦C and 5% CO2. The media
were supplemented with 10-20% fetal bovine serum (Biosera) and 1% penicillin/streptomycin (Biosera).
Cell lines were purchased from DSMZ. Both pX330-Venus sgRNA SMARCA5 intron4 (1 μg) and
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px330-Venus sgRNA SMARCA5 intron5 (1 μg) were transfected into 2.5 × 106 K562 cells using Amaxa
Cell Line Nucleofector kit (Lonza, Basel, Switzerland) and 1 × 106 K562 cells using Neon Transfection
System 10 μL Kit (Invitrogen). Cells were cultivated for 48 h, Venus-positive cells sorted on BD FACS
Aria Fusion and divided to form single cell clones on 96-well plates. DNA from growing clones was used
as a template for PCR with the following primers: forward 5′-GAGATGGAGGGCTACACTGTG-3′and
reverse 5′-GACATTCCCAAAGTCATCTAGCAG-3′. The resulting amplification produced 1175 bp
fragment from wild-type and approximately 632 bp long fragment from CRISPR/Cas9 edited allele
of the SMARCA5 gene. Cell smears (0.5–1 × 105 cells) were fixed with methanol and stained with
May–Grünwald solution (mixed 1:1 with distilled water, Penta, Limassol, Cyprus) for 5 min and
Giemsa–Romanowski solution (mixed 1:13 with distilled water, Penta) for 12 min. Cell Proliferation
Reagent WST-1 (Roche, Basel, Switzerland) was used following manufacturer’s protocol starting from
day 0 with seeding 0.5 × 104 cell/100 μL/well in triplicates and continued by daily measurement
of absorbance at 430 nm on microplate reader Infinite 200 PRO (Tecan, Männedorf, Switzerland).
Cells were simultaneously counted by Luna Automated Cell Counter (Logos Biosystems, Dongan,
South Korea).
4.3. AML Patients and Statistics
RNA-Seq data sets from AML patient samples were previously described including the informed
consent and ethical issues [29–31]. Reads were mapped with STAR aligner version 2.7.2d using GRCh37
reference and annotation version 32 from GENCODE (www.gencodegenes.org). Reads were counted
using FeatureCounts version 1.6.5, normalized to transcripts per million (TPM) and log2 transformed.
Log-rank test was performed in survival analysis, Wilcoxon test was used to assess differences in
gene expression.
4.4. Real-Time qPCR
Total RNA from wild-type (n = 10) and knockout (n = 5) K562 clones was isolated
by TRIzol Reagent (Invitrogen) and reverse-transcribed by High Capacity cDNA Reverse
Transcription kit (Thermo Fisher Scientific). Quantitative PCR was run in triplicates on
LightCycler 480 (Roche) using LightCycler 480 SYBR Green I Master (Roche) and specific primers
for human SMARCA5 (forward primer 5′-AACTTACTATCCGTTGGCGATT-3′, reverse primer
5′-GGTTGCTTTGGAGCTTTCTG-3′) and GADPH (forward 5′-AGCCACATCGCTCAGACAC-3′,
reverse primer 5′-GCCCAATACGACCAAATCC-3′) gene. Ct values served for fold-change calculation
using 2-ΔΔCt equation. Student’s t-test was used for statistical analysis.
4.5. Western Blot
Wild-type and S5KO K562 clones (1 × 10E7) were lysed in RIPA Buffer (Sigma-Aldrich)
supplemented with protease and phosphatase inhibitors (Roche). Denatured cell lysates were run on
1 mm thick 10% SDS-PAGE gel (40 μg/lane) in Mini-Protean Electrophoresis system (Bio-Rad, Hercules,
CA, USA) and semi-dry-blotted onto PVDF membrane (Bio-Rad) using Trans-Blot Turbo transfer
system (Bio-Rad). PVDF membrane was blocked for 1 h in 5% nonfat milk in 1x TBS/0.1% Tween-20 and
incubated with primary antibodies: Snf2h/ISWI (Bethyl Laboratories Inc., #A301-017A-1, Montgomery,
TX, USA) and β-actin (Santa Cruz Biotechnology, #sc-1616-R, Dallas, Texas, USA) overnight at 4 ◦C.
Horseradish peroxidase-conjugated secondary antibodies (anti-rabbit, anti-goat) visualized bands
using Pierce ECL Western Blotting substrate (Thermo Fisher Scientific).
4.6. Cytogenetics
Standard cytogenetic methods published previously [10,11] were used for preparation of slides,
with few modifications. Briefly, the K562 cells were synchronized with colcemid (10 μl/mL) at 37 ◦C
and hypotonized in 0.075 M KCl for 20 min. The cells were then fixed in three changes of cold Carnoy’s
fixative (ethanol: glacial acetic acid, 3:1) and dropped onto a slide inclined at an angle of 45 degrees
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from a height. The chromosomal preparations were air-dried overnight and stained using 5% Giemsa
blue solution (Sigma-Aldrich) prepared in standard Sorenson buffer. Preparations were inspected
under a light microscope BX43 (Olympus, Sony, Shinjuku, Japan) with microscope camera Infinity 2-2
(Lumenera, Ottawa, ON, Canada). Selected plates were photographed under a 100x immersion oil
objective using software QuickPHOTO CAMERA 3.1 (Olympus).
4.7. Hematopoietic Reconstitution
For hematopoietic reconstitution experiments, 2.5 × 106 fetal liver cells isolated from E13.5 control
(Smarca5fl/+ Rosa26eYFP/+ Vav1-iCRE) and Smarca5-deficient (Smarca5fl/− Rosa26eYFP/+ Vav1-iCRE)
with C57Bl/6J Ly5.2 background were transplanted into lethally irradiated (7.5 Gy) adult (8 weeks)
C57Bl/6J Ly5.1 recipients. After 12 days, the recipients were euthanized, and their bone marrow and
spleen were tested for the presence of donor-derived eYFP+ hematopoietic cells using flow cytometry.
The antibody panel included CD45.1, CD45.2, c-Kit, Sca1, and lineage cocktail (CD3, B220, Mac-1,
Gr-1, Ter119).
4.8. Analysis of S5KO MEF Cells
S5KO MEF cells (n = 3) were isolated from E14.5 embryos, in which the Smarca5 gene contained
the LoxP1 sites upstream and downstream of exon5 and also expressed Cre Recombinase-Estrogen
receptor fusion protein that translocated into the nucleus upon addition of 4OHT into the cultures
for 6 h. Deletion of Smarca5-exon5 represents a null allele [2]. Production of stable MEF cells was
enabled by concurrent deletion of Tp53 gene [32]. Gene targeting of the Smarca5flox/flox Cre-Esr1 cells
upon 4OHT addition was confirmed by previously published detection methods [2]. Analysis of cell
proliferation of MEFs was determined by IncuCyte (Sartorius, Göttingen, Germany) that enables
analysis in 96 wells under real-time continuous visualization and monitoring.
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Figure 1 
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Figure 2 
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Figure 5
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SUPPLEMENTARY MATERIALS 
Fusion gene detection by RNA sequencing complements diagnostics of acute myeloid 
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Supplementary Methods 
RNA-seq analysis and fusion calling 
Definition of known/true fusions and high/low evidence 
Built-in filters of fusion callers and custom blacklist of fusion genes 
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Promiscuity Score 
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Fusion Transcript Score 
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Robustness Score 
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Figure S3:
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Figure S4: DEK-NUP214
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Table S6: NRIP1 MIR99AHG
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